Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.

Trial Details

NCT ID
NCT04923542
Phase
PHASE1 / PHASE2
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Stereotactic Radiosurgery (SRS)
  • Abemaciclib
  • Endocrine therapy
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • HR+ breast cancer to fulfill the requirement of HR+ disease, a breast cancer must express (≥ 1%), by immunohistochemistry (IHC), at least 1 of the …
  • To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression o…
  • ≤ 15 brain metastases eligible for stereotactic radiation
  • Able to swallow oral medications

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →